Tracey Lodie - Gamida Cell Chief Scientific Officer
| GMDADelisted Stock | USD 1.40 0.09 6.04% |
Executive
Dr. Tracey Lodie is Chief Scientific Officer of the company. Dr. Lodie is an immunologist with over 16 years of drug discovery experience in the areas of autoimmunity, transplant biology and immunooncology. Prior to joining Gamida Cell, Dr. Lodie served as senior vice president, translational immunology at BlueRock Therapeutics, where she helped to advance their universal pluripotent stem cell platform into central nervous system, cardiovascular, and autoimmune therapeutic areas. She also served as vice president of immunology at Syros Pharmaceuticals, where she developed new autoimmunity and immunooncology research programs. Prior to Syros Pharmaceuticals, Dr. Lodie spent over 14 years at SanofiGenzyme, where she held roles of increasing responsibility. At SanofiGenzyme, Dr. Lodie was instrumental in advancing several development programs through regulatory approval in the area of transplant and autoimmunity. Dr. Lodie has experience as an academic instructor and has served in various industry related and nonprofit leadership roles, including scientific advisory boards since 2019.
| Age | 54 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Phone | 972 2 659 5666 |
| Web | https://www.gamida-cell.com |
Gamida Cell Management Efficiency
The company has return on total asset (ROA) of (0.4147) % which means that it has lost $0.4147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.0379) %, meaning that it created substantial loss on money invested by shareholders. Gamida Cell's management efficiency ratios could be used to measure how well Gamida Cell manages its routine affairs as well as how well it operates its assets and liabilities.Gamida Cell currently holds 82.94 M in liabilities. Gamida Cell has a current ratio of 2.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Gamida Cell's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Hequn Yin | Iovance Biotherapeutics | 59 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Sara Pellegrino | Iovance Biotherapeutics | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Brian MBA | Iovance Biotherapeutics | N/A | |
| Kristen Alexander | Lexicon Pharmaceuticals | 56 | |
| Caitlin Lowie | Ardelyx | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Kenneth MD | Lexicon Pharmaceuticals | 67 | |
| Jason JD | Immunitybio | 41 | |
| Chas Schultz | Lexicon Pharmaceuticals | N/A | |
| Adam Esq | BioLineRx | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
Management Performance
| Return On Equity | -11.04 | |||
| Return On Asset | -0.41 |
Gamida Cell Leadership Team
Elected by the shareholders, the Gamida Cell's board of directors comprises two types of representatives: Gamida Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gamida. The board's role is to monitor Gamida Cell's management team and ensure that shareholders' interests are well served. Gamida Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gamida Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Penny Bushell, Chief Officer | ||
| Tracey Lodie, Chief Scientific Officer | ||
| Joshua Patterson, General Officer | ||
| Paul Nee, VP Marketing | ||
| Vladimir Melnikov, Senior Manufacturing | ||
| Linda Stamler, Vice Management | ||
| Heather DiVecchia, Chief Staff | ||
| Naftali CPA, Senior Operations | ||
| RPh MBA, Chief Officer | ||
| Ronit MD, Chief Officer | ||
| Abigail Jenkins, CEO President | ||
| Mary MBA, Principal CFO |
Gamida Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gamida Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.04 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (26.80) % | |||
| Current Valuation | 70.28 M | |||
| Shares Outstanding | 132.64 M | |||
| Shares Owned By Insiders | 11.57 % | |||
| Shares Owned By Institutions | 26.48 % | |||
| Number Of Shares Shorted | 10.96 M | |||
| Price To Earning | (3.97) X | |||
| Price To Book | 117.40 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Gamida Stock
If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |